title: Cyclooxygenase-2 inhibition does not impair block bone grafts healing in rabbit model.
abstract: Success of alveolar reconstructions using onlay autogenous block bone grafts depends on their adequate integration to the recipient bed influenced by a number of local molecules. Considering the fundamental role of cyclooxygenase (COX-2) in bone repair, the aim of this study was to analyze the effect of its inhibition in the integration of endochondral (EC) iliac crest, and intramembranous (IM) calvaria bone grafts. Thirty-two rabbits were divided into 4 groups: Calvaria Control (CC) and Iliac Control--treated with oral 0.9 % saline solution, and Calvarial-NSAID (C-NSAID) and Iliac-NSAID (I-NSAID) groups--treated with oral 6 mg/Kg non-steroidal anti-inflammatory drug etoricoxib. After 7, 14, 30 and 60 days the animals were euthanized and the specimens removed for histological, histomorphometric and immunohistochemistry analysis. At day 60, a tight integration of IM blocks could be seen with the presence of remodeling bone, whereas integration of EC grafts was mainly observed at the edges of the grafts. A significant higher percentage of bone matrix in the interface region of the CC grafts in comparison to C-NSAID only at day 14, whereas no differences were detected comparing the EC grafts. No differences were observed in Runx-2 and vascular endothelial growth factor (VEGF) immunolabeling when comparing CC and C-NSAID groups, while a significant weaker Runx-2 and VEGF labeling was detected in I-NSAID group at day 60. Although some influence was detected in osteogenesis, it is concluded that drug induced inhibition of COX-2 does not impair onlay bone grafts' healing of both embryologic origins in rabbits.
authors.affiliation: Oral and Maxillofacial Surgery Doctoral's Course Program, Sagrado Coração University (USC), Rua Irmã Arminda 10-50, Jardim Brasil, Bauru, SP, CEP 17011-160, Brazil.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Moreschi
authors.forename: Claudia Cristina
authors.initials: CC
authors.lastname: Biguetti
authors.forename: Eliston
authors.initials: E
authors.lastname: Comparim
authors.forename: Leandro
authors.initials: L
authors.lastname: De Andrade Holgado
authors.forename: Paulo Domingos
authors.initials: PD
authors.lastname: Ribeiro-Junior
authors.forename: Hugo
authors.initials: H
authors.lastname: Nary-Filho
authors.forename: Mariza Akemi
authors.initials: MA
authors.lastname: Matsumoto
mesh_terms: D000818:Animals; D001857:Bone Matrix / Q000378:metabolism; D016025:Bone Transplantation; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D012886:Skull / Q000637:transplantation; D013997:Time Factors; D014182:Transplantation, Autologous; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology*
chemical_list: D050659:Core Binding Factor Alpha 1 Subunit; D052246:Cyclooxygenase 2 Inhibitors; D042461:Vascular Endothelial Growth Factor A; D051546:Cyclooxygenase 2